Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268903 | 0.90 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CDGRM5 | |
| SCHEMBL31268839 | 0.90 | KCNH2 (0.36) | PDE2APDE10AKCNH2SCN5ASCN9A | |
| SCHEMBL31269310 | 0.88 | PIK3CD (0.33) | PIK3CDGPR119 | |
| SCHEMBL31268950 | 0.86 | KCNH2 (0.32) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL30984004 | 0.86 | KCNH2 (0.32) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269380 | 0.86 | PDE2A (0.38) | PDE2APDE10AKCNH2SCN5ASCN9A | |
| SCHEMBL30983456 | 0.86 | PIK3CD (0.35) | PDE2APDE10AKCNH2SCN5ASCN9A | |
| SCHEMBL31269061 | 0.86 | MET (0.33) | PDE2APDE10AKCNH2SCN5ASCN9A | |
| SCHEMBL31269189 | 0.85 | HRH4 (0.33) | PDE2AKCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL30983375 | 0.85 | PDE2A (0.35) | PDE2APDE10AKCNH2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |